Cargando…

Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies

COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When now repurposing a drug, namely an aptamer tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Haberland, Annekathrin, Krylova, Oxana, Nikolenko, Heike, Göttel, Peter, Dallmann, Andre, Müller, Johannes, Weisshoff, Hardy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157297/
https://www.ncbi.nlm.nih.gov/pubmed/34069827
http://dx.doi.org/10.3390/v13050932
_version_ 1783699652020797440
author Haberland, Annekathrin
Krylova, Oxana
Nikolenko, Heike
Göttel, Peter
Dallmann, Andre
Müller, Johannes
Weisshoff, Hardy
author_facet Haberland, Annekathrin
Krylova, Oxana
Nikolenko, Heike
Göttel, Peter
Dallmann, Andre
Müller, Johannes
Weisshoff, Hardy
author_sort Haberland, Annekathrin
collection PubMed
description COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When now repurposing a drug, namely an aptamer that interacts with SARS-CoV-2 proteins for COVID-19 treatment (BC 007), which is, however, a neutralizer of pathogenic autoantibodies in its original indication, the possibility of also binding and neutralizing anti-SARS-CoV-2 antibodies must be considered. Here, the highly specific virus-neutralizing antibodies have to be distinguished from the ones that also show cross-reactivity to tissues. The last-mentioned could be the origin of the widely reported SARS-CoV-2-induced autoimmunity, which should also become a target of therapy. We, therefore, used enzyme-linked immunosorbent assay (ELISA) technology to assess the binding of well-characterized publicly accessible anti-SARS-CoV-2 antibodies (CV07-209 and CV07-270) with BC 007. Nuclear magnetic resonance spectroscopy, isothermal calorimetric titration, and circular dichroism spectroscopy were additionally used to test the binding of BC 007 to DNA-binding sequence segments of these antibodies. BC 007 did not bind to the highly specific neutralizing anti-SARS-CoV-2 antibody but did bind to the less specific one. This, however, was a lot less compared to an autoantibody of its original indication (14.2%, range 11.0–21.5%). It was also interesting to see that the less-specific anti-SARS-CoV-2 antibody also showed a high background signal in the ELISA (binding on NeutrAvidin-coated or activated but noncoated plastic plate). These initial experiments suggest that the risk of binding and neutralizing highly specific anti-SARS CoV-2 antibodies by BC 007 should be low.
format Online
Article
Text
id pubmed-8157297
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81572972021-05-28 Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies Haberland, Annekathrin Krylova, Oxana Nikolenko, Heike Göttel, Peter Dallmann, Andre Müller, Johannes Weisshoff, Hardy Viruses Brief Report COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When now repurposing a drug, namely an aptamer that interacts with SARS-CoV-2 proteins for COVID-19 treatment (BC 007), which is, however, a neutralizer of pathogenic autoantibodies in its original indication, the possibility of also binding and neutralizing anti-SARS-CoV-2 antibodies must be considered. Here, the highly specific virus-neutralizing antibodies have to be distinguished from the ones that also show cross-reactivity to tissues. The last-mentioned could be the origin of the widely reported SARS-CoV-2-induced autoimmunity, which should also become a target of therapy. We, therefore, used enzyme-linked immunosorbent assay (ELISA) technology to assess the binding of well-characterized publicly accessible anti-SARS-CoV-2 antibodies (CV07-209 and CV07-270) with BC 007. Nuclear magnetic resonance spectroscopy, isothermal calorimetric titration, and circular dichroism spectroscopy were additionally used to test the binding of BC 007 to DNA-binding sequence segments of these antibodies. BC 007 did not bind to the highly specific neutralizing anti-SARS-CoV-2 antibody but did bind to the less specific one. This, however, was a lot less compared to an autoantibody of its original indication (14.2%, range 11.0–21.5%). It was also interesting to see that the less-specific anti-SARS-CoV-2 antibody also showed a high background signal in the ELISA (binding on NeutrAvidin-coated or activated but noncoated plastic plate). These initial experiments suggest that the risk of binding and neutralizing highly specific anti-SARS CoV-2 antibodies by BC 007 should be low. MDPI 2021-05-18 /pmc/articles/PMC8157297/ /pubmed/34069827 http://dx.doi.org/10.3390/v13050932 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Haberland, Annekathrin
Krylova, Oxana
Nikolenko, Heike
Göttel, Peter
Dallmann, Andre
Müller, Johannes
Weisshoff, Hardy
Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
title Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
title_full Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
title_fullStr Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
title_full_unstemmed Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
title_short Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
title_sort aptamer bc 007’s affinity to specific and less-specific anti-sars-cov-2 neutralizing antibodies
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157297/
https://www.ncbi.nlm.nih.gov/pubmed/34069827
http://dx.doi.org/10.3390/v13050932
work_keys_str_mv AT haberlandannekathrin aptamerbc007saffinitytospecificandlessspecificantisarscov2neutralizingantibodies
AT krylovaoxana aptamerbc007saffinitytospecificandlessspecificantisarscov2neutralizingantibodies
AT nikolenkoheike aptamerbc007saffinitytospecificandlessspecificantisarscov2neutralizingantibodies
AT gottelpeter aptamerbc007saffinitytospecificandlessspecificantisarscov2neutralizingantibodies
AT dallmannandre aptamerbc007saffinitytospecificandlessspecificantisarscov2neutralizingantibodies
AT mullerjohannes aptamerbc007saffinitytospecificandlessspecificantisarscov2neutralizingantibodies
AT weisshoffhardy aptamerbc007saffinitytospecificandlessspecificantisarscov2neutralizingantibodies